Geron Q2 net product revenue $49.0M, net loss narrows to $16.4M; new CEO named

GERON CORP

2025-Q2 EPS reported -$0.05 revenue$88,639,000

Net product revenue of $49.0M from RYTELO in Q2 2025, up 24% QoQ; demand up 17% QoQ with over 1,000 ordering accounts.
Net loss of $16.4M ($0.02/share) vs $67.4M loss ($0.10) in Q2 2024, driven by rising RYTELO sales and lower R&D costs.
Phase 3 IMpactMF trial in myelofibrosis now over 95% enrolled; full enrollment expected by year-end 2025.
Harout Semerjian appointed President and CEO; seasoned commercial hematology and oncology leader.
FY2025 operating expense guidance maintained at $270M-285M; cash and securities $432.6M as of June 30.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.